CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

Published Date: 31 Mar 2026

A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.

Read Full News

Latest News

Biocomputer From Human Neurons Plays Doom, Raises Ethics

A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.

EMA OKs Two Treatments for Small Cell Lung Cancer

Both drugs increase overall and progression-free survival.

Nodal Response After Chemo Helps Tailor Breast Radiotherapy

Ten-year findings suggest some patients may safely receive less treatment, potentially lowering side effects without raising recurrence risk.

Delaying Pegfilgrastim May Curb Bone Pain in Breast Cancer

Pegfilgrastim helps prevent myelosuppression in women undergoing chemotherapy for breast cancer but can also cause severe bone pain. A new study suggests a simple solution.

From Pathology to Precision: The Story of Leukemia Therapy

From 19th century ‘white blood’ observations and pathological anatomy to the discovery of BCR-ABL and imatinib, leukemia care evolved from near-certain death to precise, life-extending therapies.

Todays Updates

Can MRI Curb Chemo Overtreatment in Breast Cancer?

MRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.

Subcutaneous Toripalimab Matches IV Formulation in NSCLC

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

New Gene Therapy Nears EU Nod for Bladder Cancer

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

Todays Updates

Can MRI Curb Chemo Overtreatment in Breast Cancer?

MRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.

Subcutaneous Toripalimab Matches IV Formulation in NSCLC

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

New Gene Therapy Nears EU Nod for Bladder Cancer

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

Latest News

A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.

The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.

Both drugs increase overall and progression-free survival.

Ten-year findings suggest some patients may safely receive less treatment, potentially lowering side effects without raising recurrence risk.

Pegfilgrastim helps prevent myelosuppression in women undergoing chemotherapy for breast cancer but can also cause severe bone pain. A new study suggests a simple solution.

From 19th century ‘white blood’ observations and pathological anatomy to the discovery of BCR-ABL and imatinib, leukemia care evolved from near-certain death to precise, life-extending therapies.

News All Time

Chemoimmunotherapy Boosts Head and Neck Cancer Response

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

Have the Harms of Lung Cancer Screening Been Exaggerated?

Three medical societies claim recent studies have overestimated the potential harms from lung cancer screening and may be deterring patients. Not everyone agrees.

Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy

Despite FDA package insert recommendations, most patients with breast cancer who are prescribed CDK4/6 inhibitors do not receive liver function tests before starting treatment.

Alternative Medicine for Breast Cancer: Study Raises Concern

Patients who receive both standard medical treatment and complementary and alternative therapies have higher mortality — possibly due to reduced use of endocrine therapy and radiation.

Biomarker Flags 10-Fold Recurrence Risk in Testicular Cancer

MiR-371 isn’t ready for the clinic yet, but it is ready for interventional trials to see if it can refine adjuvant chemotherapy decisions in stage I testicular cancer.

FDA Approves New Drug Combo for RR Multiple Myeloma

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

Current treatment options include surgery and chemotherapy, but chemotherapy’s benefits are often modest and can cause substantial side effects.

SBRT May Beat Brachytherapy in Prostate Cancer

In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.

When in Breast Cancer Treatment Are CDK4/6 Inhibitors Best?

Researchers examined whether CDK4/6 inhibitors lead to better overall survival when used as first- or second-line treatment.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

Patients with breast cancer living in states with expanded Medicaid eligibility, have seen survival gains, raising more concerns about the impact of recent changes to the program.

Cancer and HIV Vaccines Enter the Therapeutic Era

Therapeutic vaccines are advancing in oncology and HIV, with the aim of retraining immune responses to target tumors and persistent viral reservoirs with precision.

FDA Approves Monthly Dosing of Rybrevant Faspro for NSCLC

The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.

Recommended News For You

Common intracellular toxin could help fight leukemia

For fit patients with CLL, frontline venetoclax-ibrutinib improves survival.

Cardiorespiratory fitness lowers the risk of colon, lung, and prostate cancer in MEN and lowers mortality from these diseases.

Investigations may result in novel combination therapies for early-stage lung cancers.

Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing

Advanced imaging, targeted therapy help men with prostate cancer safely defer surgery and radiation therapy

In cancer patients taking immune checkpoint inhibitors, systematic vitamin D supplementation improves outcomes.

Recommended Articles For You

Hemophilia Beyond Boundaries: Unconventional Therapies in Bleeding Disorder Care 

Emicizumab in Infants with Severe Hemophilia A: HAVEN 7 Phase 3b Trial Insights 

Exploring the Impact of Adrenal Myelolipoma on the Human Body 

Toripalimab + Nab-Paclitaxel in PD-L1+ TNBC: Phase 3 TORCHLIGHT Trial Results 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Distribution of fat could influence cancer risk, study suggests

2.

While most cancer screenings won't prolong lives, there are still good reasons to continue screening.

3.

Ignoring Colonoscopy Advice; Dry Mouth Acupuncture; Inflamed Tongue, Then Cancer.

4.

DBT Reduced Suicide Attempts in Adolescents with Bipolar Disorder.

5.

With the use of a novel sequencing technique, pediatric bone marrow transplant mortality can be predicted by analyzing lung microbiomes.

1.

Know About Lymphangioma: Symptoms, Causes, and Treatments

2.

What You Need to Know about Hairy Cell Leukemia: A Comprehensive Guide 

3.

The Essential Guide to Understanding Fibrinogen and Its Role in Blood Clotting 

4.

Asymptomatic Thrombocytopenia: Unraveling the Enigma of Low Platelet Counts Without Symptoms

5.

ctDNA in Oncology: Transforming MRD Assessment, Disease Tracking, and Early Cancer Detection

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis

2.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I

3.

Navigating the Complexities of Ph Negative ALL - Part VII

4.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot